• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Takeda to Expand U.S. Footprint

    Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines

    WuXi STA Opens High-Potency API Plant

    Catalent Expands Primary Packaging Capabilities at its Shiga, Japan Facility

    Phastar Appoints Chris Schoonmaker as Chief Operations Officer
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Takeda to Expand U.S. Footprint

    Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines

    WuXi STA Opens High-Potency API Plant

    Catalent Expands Primary Packaging Capabilities at its Shiga, Japan Facility

    Shimadzu Scientific Instruments Extends HQ Campus
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Takeda to Expand U.S. Footprint

    Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines

    Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK

    EQT Private Equity Acquires SPT Labtech from Battery Ventures

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Biosynth Carbosynth

    Societal CDMO

    CMC Pharmaceuticals

    Qosina

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Biosynth Carbosynth

    Societal CDMO

    CMC Pharmaceuticals

    Qosina

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Oral Solids Market Update

    Pharmaceutical CDMOs continue to invest in oral solid dose development and manufacturing capabilities.

    Oral Solids Market Update
    Tim Wright, Editor, Contract Pharma03.11.22
    Oral solids are cost-effective, easy to manufacture and patient-friendly, making them the most common dosage form in the pharmaceutical industry. In addition, advances in drug delivery technology, such as targeted drug delivery and sustained release dosage forms, are enabling oral solids to achieve even greater levels of bioavailability while reducing the frequency of drug administration. Other benefits exist in terms of relatively uncomplicated packaging needs and storage and distribution requirements due to chemical and physical stability.

    As the most preferred drug delivery form, oral solids are used across a wide spectrum of the pharmaceutical landscape. In fact, the small molecule outsourcing market is expected to reach $69.4 billion by 2024, with the demand being driven by complex molecules, according to Visiongain’s report, “Pharmaceutical Contract Manufacturing Market 2019-2029.”

    Over the past several months, contract development and manufacturing organizations (CDMOs) have continued to invest in and expand their oral solid dosage (OSD) development and manufacturing capabilities to meet the growing demands of the market. Some recent and notable examples follow.

    CordenPharma Acquires Three GMP Manufacturing Facilities
    CordenPharma, a full-service CDMO supplying APIs, excipients, drug products and associated packaging services, has completed the acquisition of three manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma Fribourg S.A. (including its Ettingen branch) in Switzerland, and Corden Pharma Lisbon S.A. in Portugal.

    The acquisition of the Vifor Pharma manufacturing sites expands CordenPharma’s capabilities and capacities in the manufacturing of non-sterile drug product dosage forms, including but not limited to, OSD forms such as tablets and capsules. With the addition of these three new facilities, CordenPharma’s global network now consists of 12 locations (11 GMP sites and one R&D laboratory), supported by more than 2,600 employees generating expected sales of over €800 million in 2022.

    Catalent Launches Xpress Pharmaceutics Service
    Catalent recently launched its new Xpress Pharmaceutics service, designed to accelerate the development of oral drugs through Phase 1 clinical studies. By integrating formulation development, on-demand clinical manufacturing, regulatory support and clinical testing, the approach can reduce both the cost and time taken to complete first-in-human trials, according to the CDMO.

    Xpress Pharmaceutics allows Catalent to work alongside innovator and clinical research organizations (CROs), and provide formulated clinical trial material with the necessary stability data that can be prepared for dosing patients at the clinical site, in line with adaptive study protocols. This approach provides a faster alternative to the traditional clinical development model, and offers the advantage of flexible dose and/or formulation composition adjustment during a clinical trial, guided by real-time clinical data.

    The service will be delivered by formulation development experts at Catalent’s facilities in Nottingham, UK and Beinheim, France and supported by the company’s global regulatory affairs team. To further support accelerated timelines, Catalent has a pre-qualified CRO partner, allowing seamless transition from manufacturing into clinical testing.

    Procaps Acquires First U.S. Softgel Production Facility
    Barranquilla, Colombia-based Procaps Group, an integrated international healthcare and pharmaceutical company, closed an asset purchase agreement to acquire an 86,000 square foot pharmaceutical production facility located in West Palm Beach, FL with production capacity of approximately 1.8 billion capsules per year for its iCDMO (integrated contract development and manufacturing organization) business unit, and is expected to increase the company’s product development capabilities by more than 70%.

    The soft gelatin capsule is a solid dosage form composed of two gelatin films that contain semisolid or liquid APIs protected by an external, hermetically sealed cover. Softgels are designed to deliver high precision dosage by achieving homogeneity of ingredients. The softgel capsules are well recognized in the supplement, over-the-counter (OTC) and the prescription market for improving patient adherence to the drug and therapy by facilitating swallowing due to the texture of its shell.

    The pharmaceutical production facility was purchased from Strides Pharma, a U.S. subsidiary of the Indian-based pharmaceutical corporation, the Strides Group. The facility is U.S. FDA approved and, in addition to the manufacturing capabilities, it offers development and analytical testing capacities, which the company says will become an important alternative for new pharmaceutical and OTC developments in highly regulated markets worldwide. Core assets included in the acquisition were several softgel encapsulation lines, new critical support systems, automated packaging line capabilities, as well as development facilities including pilot and scale up capabilities. Procaps Group expects the facility to begin operations in May of 2022.

    Eurofins CDMO Expands Spray Drying Capabilities
    Eurofins CDMO is expanding its spray dry development and production services in North America. The Canadian facility, located in Mississauga, Ontario, has expanded its cGMP spray drying capabilities with the addition of a GEA Mobile Minor spray drying system and dedicated 500 square foot clean room.

    With this expansion, Eurofins CDMO can further complement a broad range of services specializing in solubility enhancement for clinical development and small-scale commercial programs. Its process capabilities include solvent or aqueous systems, highly potent compounds, API and drug product development and manufacturing, solid state characterization, oral solid and inhalation dosage forms.

    The expansion of spray drying at Eurofins CDMO provides continued support of clinical development programs where formulation enabling is required for poorly soluble compounds. The new spray dry system enables manufacturing of solid dispersions at multi-kilo scale in support of a wide range of finished dosage forms for early clinical through to niche commercial programs.

    Piramal Strengthens North American Capabilities
    The CDMO Piramal Pharma Solutions has recently added development- and commercial-scale roller compaction technology to its Sellersville, PA drug product facility. The addition of the Gerteis Macro-pactor equipment, which is designed to handle both development and commercial scale roller compaction, enhances the site’s dry granulation and scale-up capabilities.


    Piramal Pharma solutions enhances solid oral dosage formulation capabilities in North America with the Gerteis Macro-pactor, known as the market leader in roller compaction technology.

    Market data indicates that more than 20% of the new chemical entities being developed use roller compaction technology in their development and/or commercialization. In addition, roller compaction is an excellent technology for processing certain APIs, according to the company. The densification of dry blended powders is a critical capability that is required to handle products with poor API flow properties and instances where the API is moisture sensitive. Wet granulation is sometimes used to overcome these challenges, but many APIs are not amenable to wet granulation. In such cases, roller compaction provides a viable option to densify material and generate granules which can be further processed into capsules or tablets.

    The Gerteis Macro-pactor is a versatile piece of equipment, with the ability to handle 100-300 gram batches for small-scale development as well as larger volumes when used in continuous mode. It is recognized as an effective solution for both small-scale development requiring roller compaction technology and larger scale clinical and commercial batches as the compounds move forward in the development cycle.

    New CDMO Astrea Pharma Buys Recipharm Site
    A newly established CDMO, Astrea Pharma, focused on small molecule oral solid dosage forms, recently purchased Recipharm’s solid dose manufacturing site at Fontaine-lès-Dijon, France. Under Recipharm’s ownership, Fontaine has developed extensive experience manufacturing and packaging tablets and capsules. The capabilities fit well with Astrea’s ambitions to grow a broad range of different processing, filling and packaging technologies, as well as a wide geographical reach.

    Astrea’s owners are veterans in the CDMO industry and have the financial backing of the French long-term investment company Groupe Chevrillon, a family-owned business with a strong track record of investment in industrial and service companies.

    Metrics Contract Services Adds New Equipment
    Metrics Contract Services, the contract pharmaceutical development and manufacturing division of Mayne Pharma, has invested in additional equipment to enhance capacity in early phase drug development. Another Xcelodose 600S precision powder micro-dosing system will further provide capacity and efficiency improvements in meeting increasing demand for preclinical and early phase clinical GMP supply.

    Metrics’ new Xcelodose 600S is a strategic addition for Metrics’ formulation development team. The 600S can dispense dose weights as low as 100 micrograms, allowing for precise, accurate and repeated filling of capsules and other small dose containers without excipients or bulking agents. Most formulated products can also be filled without segregation. Metrics will install the new Xcelodose 600S in its state-of-the-art facility in Greenville, NC.

    Hovione Enters Dispersome Technology Partnership
    Hovione, a CDMO and provider of spray drying and particle engineering services, has entered a partnership with Zerion Pharma to market and commercialize Dispersome, Zerion´s proprietary solubility enhancement technology platform.

    Zerion’s technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions by spray drying. By combining Dispersome technology with Hovione’s spray drying capabilities, experience in development, scale-up and GMP manufacturing, the CDMO has strengthened its position in amorphous solid dispersions, coming up with innovative solutions to overcome a prevalent challenge faced by the industry: low drug solubility. 

    Syntegon & Bayer Partner to Expand Continuous Manufacturing for Solid Dosage Forms

    Collaboration aims to further develop the Xelum platform and tap its potential more quickly.

    Syntegon Pharma Technology, a supplier of process technology and packaging solutions for the pharmaceutical industry, has entered a strategic partnership with Bayer for the development of new continuous manufacturing processes for oral solid dosage (OSD) forms.

    The cooperation is based on the Xelum platform developed by the Syntegon subsidiary Hüttlin, which the partners intend to advance together and establish as a standard in the pharmaceuti-cal industry.

    Its main advantage and a novelty in continuous pharmaceutical production is the previously un-attained precise dosing of active ingredients. At the same time, fluid bed granulation provides granules with outstanding properties.

    Tapping the potential of the Xelum platform
    Fluid bed granulation remains the most flexible technology for the production of solid oral drug formulations. It is well established and the ease of transfer from the currently predominant batch process to continuous production is of high value to pharmaceutical companies. Continu-ous manufacturing makes it possible to further increase quality assurance in production and make new drugs available to patients faster.

    Uwe Harbauer, head of Syntegon’s pharma business unit, said, “Together with Bayer, we will continue to develop our Xelum platform and tap its potential more quickly. This will enable us to align our technology even more closely with specific customer requirements. The goal is to realize a continuous line that covers all steps from powder to coated tablet.”

    A unique approach to continuous manufacturing
    While other continuous processes rely on screw granulation, Syntegon's Xelum platform uses fluid bed granulation, which has been well established for decades. Since granulation and dry-ing take place in the same process room, there is no need to transport wet granules. The sys-tem doses, mixes and granulates defined sub-quantities of the product, so-called X-Keys, which continuously run through the process chain and are removed from the system successively. The X-keys ensure the traceability of the ingredients, which is essential for pharmaceutical produc-tion, at all times. Xelum requires neither technology transfer nor scale-up. Product develop-ment and manufacturing are carried out according to the same principles and recipes.

    In addition to further developing the Xelum platform, Syntegon's main goal is to fulfill the so-called “continuous promise,” according to Harbauer. “We want our systems to enable higher quality assurance at lower development costs,” he said. “In combination with higher flexibility in batch sizes and technology, this gives us a very positive outlook for the continuous future.”

    Related Content

      Loading, Please Wait..
      Trending
      • Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
      • Almac Participates In Global Clinical Supply BlockChain Working Group
      • Regulatory Report: Analytical Procedure Development
      • Shimadzu Scientific Instruments Extends HQ Campus
      • Batavia Enters Commercial Manufacturing Business
      Breaking News
      • Takeda to Expand U.S. Footprint
      • Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines
      • WuXi STA Opens High-Potency API Plant
      • Catalent Expands Primary Packaging Capabilities at its Shiga, Japan Facility
      • Phastar Appoints Chris Schoonmaker as Chief Operations Officer
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Pharmavite Expands in Ohio with $200 Million Investment
      Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company
      Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products
      Coatings World

      Latest Breaking News From Coatings World

      Clariant’s Launches Dispersogen Flex 100
      Lincoln Tech Enters Partnership with AkzoNobel
      AkzoNobel Launches International Interzone 945GF
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      ENDRA Life Sciences Issued 27th Patent
      AI-Enabled SKOUT Device Improves Colorectal Cancer Screening
      Simon Johnson Appointed as Senior Business Development VP at MedAcuity
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Takeda to Expand U.S. Footprint
      Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines
      WuXi STA Opens High-Potency API Plant
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Latest Updates About Cosmoprof North America
      Meet the Clean Beauty Brand for Dogs
      Paco Rabanne Introduces Elle Fanning as Ambassador for New ‘Fame’ Fragrance
      Happi

      Latest Breaking News From Happi

      Two-Part Skincare Product Patented by Estée Lauder Companies
      American Cleaning Institute Pens Letter to Congress Encouraging Examination of Recyclability Improvements
      The Expert Panel for Fragrance Safety Celebrates 55 Years
      Ink World

      Latest Breaking News From Ink World

      INX Launches INXFlex Contour for Shrink Sleeve Market
      Xerox Announces Unexpected Passing of Vice Chairman and CEO John Visentin
      MNYPIA Golf Outing Set to Tee Off on Aug. 17
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Meyers purchased by third generation of Dillon family
      Epson now shipping ColorWorks C4000 inkjet label printer
      Nobelus launches new films for prime labels
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      What You’re Reading on Nonwovens-Industry.com
      Daio, Livedo Partner to Recycle Diapers
      Suominen Launches Hydraspun Reserve
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      3D Systems and EMS-GRILTECH Enter Strategic Partnership
      AIP Researchers Develop Microfluidic-Based Soft Robotic Prosthetic
      David Sharp Named Global Marketing VP at Catalyst OrthoScience
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Impinj Launches E910 RFID Reader Chip for Next Generation Enterprise IoT
      onsemi Receives Recognition for Sustainability for Third Straight Year
      Xerox Announces the Unexpected Passing of Vice Chairman and CEO John Visentin

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login